glp-1 receptors Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1R Signaling and Functional Molecules
Description
The SELECT cardiovascular outcomes trial showed that semaglutide 2.4 mg significantly reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in patients with established cardiovascular disease and overweight or obesity, even without type 2 diabetes
doi: 10.1038/ijo.2013.149 91 le RouxCWAstrupAFujiokaKGreenwayFLauDCWVan GaalLet al
Why do clinical trial results differ from real-world outcomes
T2D, type 2 diabetes mellitus
Experts say that patients and clinicians must be aware of severe side effects like gastroparesis and its consequences
